TP53 and breast carcinoma: To verify this phenomenon in clinical samples, we analyzed immunocyte profiles in breast cancers developed in patients carrying the pathogenic BRCA1 mutations in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database.[qv: 37] It was reported that nearly all luminal breast cancers carry point mutations in TP53,[qv: 38] so we used breast cancer patients with a TP53 R175 mutation, a hotspot mutation as a control group.